NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









CUTISS AG

CUTISS AG

Private
SchlierenHealthcare & Life Scienceshttps://cutiss.swiss/

Last Round

Series C

Sep 10, 2025

Total Funding Raised

$101.96M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

CUTISS AG is a Swiss life sciences company that develops personalized, bio-engineered skin grafts to treat large and deep skin defects.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Medical Devices, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Hardware Sales

AI Layer

Non-AI

Keywords

regenerative medicineskin grafttissue engineeringpersonalized medicinelab-grown skinbiotechautologous therapyburn treatmentbioreactorcell therapyGMPgood manufacturing practicemedical devicebio-manufacturingbio-printing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

CUTISS AG Comparables

Compare CUTISS AG with similar companies based on industry and business-model similarity.

CUTISS AG comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
BioLab Sciences
80%
PolarityBio, Inc.
77%
Keenova Therapeutics plc
77%

CUTISS AG Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CSep 10, 2025
GrantMay 2, 2023
Series BJun 29, 2020
GrantAug 19, 2019
GrantSep 1, 2018
Series A
Jun 20, 2018

Key People

Founding team and executive leadership

Daniela Marino

Chief Executive Officer

Executive Team

Anke Ness

Interim CFO

Executive Team

CUTISS AG Investors

Notable investors and investment history

CUTISS AG investors
InvestorRounds
Horizon 2020Grant
European CommissionGrant
Yellowstone Holding AGSeries A
Swisspreneur SyndicateSeries C
Wyss FoundationSeries B
InnosuisseGrant
University of ZurichConvertible Debt

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 20, 2026

    Launched a process for manufacturing personalized, living skin.

  • Oct 1, 2025

    denovoSkin™ successfully completed Phase I clinical trials in burns patients.

CUTISS AG Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

CUTISS AG Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about CUTISS AG's valuation, stock price, and market status.

Firmographic Details

HeadquartersSchlieren
Employee Range65
Year Founded2017
Last FundingSep 10, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.